XOMA Royalty Corporation (NASDAQ:XOMA) Given Consensus Rating of “Hold” by Brokerages

XOMA Royalty Corporation (NASDAQ:XOMA) has been assigned a consensus recommendation of “Hold” from the seven analysts that are currently covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $53.75.

Several research firms recently weighed in on XOMA. Benchmark cut shares of XOMA Royalty from a “buy” rating to a “hold” rating in a research note on Friday, May 22nd. HC Wainwright cut shares of XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 target price for the company. in a research note on Thursday, April 30th. Lucid Cap Mkts cut shares of XOMA Royalty from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 27th. Zacks Research raised shares of XOMA Royalty from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 8th. Finally, Weiss Ratings raised shares of XOMA Royalty from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, May 29th.

XOMA Royalty Stock Performance

Shares of NASDAQ:XOMA opened at $41.70 on Thursday. The company has a market capitalization of $522.92 million, a price-to-earnings ratio of 26.56 and a beta of 0.88. The firm’s 50 day simple moving average is $38.64 and its 200 day simple moving average is $31.33. The company has a debt-to-equity ratio of 0.96, a current ratio of 3.59 and a quick ratio of 3.59. XOMA Royalty has a fifty-two week low of $22.29 and a fifty-two week high of $42.81.

XOMA Royalty (NASDAQ:XOMA) last announced its earnings results on Tuesday, May 12th. The biotechnology company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.02). XOMA Royalty had a return on equity of 12.56% and a net margin of 53.46%.The company had revenue of $12.32 million for the quarter, compared to analyst estimates of $13.91 million. As a group, sell-side analysts forecast that XOMA Royalty will post 0.9 earnings per share for the current year.

Institutional Investors Weigh In On XOMA Royalty

A number of institutional investors have recently modified their holdings of XOMA. Vanguard Group Inc. raised its stake in XOMA Royalty by 4.6% in the third quarter. Vanguard Group Inc. now owns 668,111 shares of the biotechnology company’s stock valued at $25,749,000 after purchasing an additional 29,298 shares in the last quarter. Opaleye Management Inc. raised its stake in XOMA Royalty by 14.7% in the fourth quarter. Opaleye Management Inc. now owns 292,590 shares of the biotechnology company’s stock valued at $7,780,000 after purchasing an additional 37,503 shares in the last quarter. Geode Capital Management LLC raised its stake in XOMA Royalty by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 221,566 shares of the biotechnology company’s stock valued at $5,893,000 after purchasing an additional 9,589 shares in the last quarter. Woodline Partners LP raised its stake in XOMA Royalty by 16.5% in the third quarter. Woodline Partners LP now owns 209,945 shares of the biotechnology company’s stock valued at $8,091,000 after purchasing an additional 29,715 shares in the last quarter. Finally, State Street Corp raised its stake in XOMA Royalty by 4.7% in the fourth quarter. State Street Corp now owns 174,908 shares of the biotechnology company’s stock valued at $4,651,000 after purchasing an additional 7,873 shares in the last quarter. Institutional investors own 95.92% of the company’s stock.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.